<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85542">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01732250</url>
  </required_header>
  <id_info>
    <org_study_id>0276-12-RMC</org_study_id>
    <nct_id>NCT01732250</nct_id>
  </id_info>
  <brief_title>Multicenter Open-label Randomized Controlled Trial (RCT) to Compare Colistin Alone Versus Colistin Plus Meropenem</brief_title>
  <official_title>Multicenter Open-label RCT to Compare Colistin Alone vs. Colistin Plus Meropenem</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mical Paul</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <authority>Israel: Ethics Commission</authority>
    <authority>Greece: Ethics Committee</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the addition of meropenem to colistin is
      better than colistin alone in the treatment of clinically significant infections caused by
      multi-drug resistant bacteria
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Clinical success</measure>
    <time_frame>14 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>defined as a composite of all of the following, all measured at 14 days:
Patient alive
Systolic blood pressure &gt;90 mmHg without need for vasopressor support
Stable or improved SOFA score, define as:
for baseline SOFA ≥ 3: a decrease of at least 30%;
for baseline SOFA &lt;3: stable or decreased SOFA score
For patients with HAP/ VAP, PaO2/FiO2 ratio stable or improved
For patients with bacteremia, no growth of the initial isolate in blood cultures taken on day 14 if patient still febrile</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary outcomes and adverse events</measure>
    <time_frame>14 and 28 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>14 and 28-day all-cause mortality.
If patients are discharged or death occurs before end of follow-up (day 28), we will end data collection at that date. We will attempt to determine survival status at day 28 for all patients (central registry in Israel; re-admissions, rehabilitation centers, hospital transfers in Greece and Italy).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical success with modification</measure>
    <time_frame>14 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical success, but with modification to the antibiotic treatment not permitted by protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to defervescence</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>defined as time to reach a temperature of &lt;38°C with no recurrence for 3 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to weaning</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time to weaning from mechanical ventilation in VAP for patients weaned alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to hospital discharge</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time to hospital discharge for patient discharged alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological failure</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Microbiological failure, defined as isolation of the initial isolate (phenotypically identical) in a clinical sample (blood or other) 7 days or more after start of treatment or its identification in respiratory samples.
For all patients with VAP/ HAP sputum or tracheal aspirates will be obtained on day 7, regardless of clinical response
For all patients with UTI, a repeat urine culture will be obtained on day 7, regardless of clinical response
For patients with bacteremia, blood cultures will be repeated on day 7 and 14, only if the patient is febrile at that time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Superinfections</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Defined as a new clinically or microbiologically-documented infections by CDC criteria within 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New resistant infection</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Colonization or infection by newly-acquired (other species than the initial infection) carbapenem-resistant or colistin-resistant Gram-negative bacteria. Colonization will be assessed by rectal surveillance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CDAD</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Clostridium-difficile-associated diarrhea, defined by diarrhea with a positive C. difficile toxin test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Gram-Negative Bacterial Infections</condition>
  <arm_group>
    <arm_group_label>Colistin and Meropenem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV meropenem, 2 gram q8h, adjusted for renal function IV Colistin with loading dose of 9 mil IU units, Maintenance dose 4.5 mil IU q12h, adjusted for renal function</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colistin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV Colistin with loading dose of 9 mil IU units, Maintenance dose 4.5 mil IU q12h, adjusted for renal function</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colistin</intervention_name>
    <description>IV Colistin with loading dose of 9 mil IU units, Maintenance dose 4.5 mil IU q12h, adjusted for renal function, for 10 days.</description>
    <arm_group_label>Colistin and Meropenem</arm_group_label>
    <arm_group_label>Colistin</arm_group_label>
    <other_name>Colistimethate Sodium</other_name>
    <other_name>Coliracin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meropenem</intervention_name>
    <description>IV meropenem, 2 gram q8h, adjusted for renal function, for up to 10 days.</description>
    <arm_group_label>Colistin and Meropenem</arm_group_label>
    <other_name>Meronem</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult inpatients

          -  Clinically significant, microbiological-documented infection caused by
             carbapenem-resistant and colistin-susceptible Gram-negative bacteria and identified
             according to CDC criteria- blood stream infections, hospital acquired pneumonia,
             ventilator associated pneumonia, and urinary tract infections

          -  Patient recruitment will occur only after microbiological documentation and
             susceptibility testing. Patients will be included within 96 hours of the time the
             index culture was taken (typically within 48 hours of isolate identification),
             regardless of the antibiotic treatment administered during this time period.

        Exclusion Criteria:

          -  Previous inclusion in the trial. Patients will be included in the RCT only once for
             the first identified episode of infection

          -  Pregnant women

          -  Epilepsy or prior seizures

          -  Known allergy to colistin or a carbapenem
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johan Mouton, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mical Paul, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam Health Care Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mical Paul, MD</last_name>
    <email>paulm@post.tau.ac.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Atikkon Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diamantis Plachouras, MD</last_name>
    </contact>
    <investigator>
      <last_name>Diamantis Plachouras, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Laikon Hosptial</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diamantis Plachouras, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Diamantis Plachouras, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mical Paul, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mical Paul, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petach-Tikvah</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonard Leibovici, MD</last_name>
    </contact>
    <investigator>
      <last_name>Leonard Leibovici, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tel-Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel-Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yehuda Carmeli, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yehuda Carmeli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Agostino Gemelli Hospital</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location_countries>
    <country>Greece</country>
    <country>Israel</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 6, 2013</lastchanged_date>
  <firstreceived_date>November 19, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rabin Medical Center</investigator_affiliation>
    <investigator_full_name>Mical Paul</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Gram-Negative Bacterial Infections</keyword>
  <keyword>Resistant Bacteria</keyword>
  <keyword>Drug Resistance, Bacterial</keyword>
  <keyword>Colistin</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Gram-Negative Bacterial Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colistin</mesh_term>
    <mesh_term>Meropenem</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
